{"id":933998,"date":"2026-02-04T10:43:38","date_gmt":"2026-02-04T15:43:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\/"},"modified":"2026-02-04T10:43:38","modified_gmt":"2026-02-04T15:43:38","slug":"nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\/","title":{"rendered":"NodThera Appoints Geoff McDonough, M.D., as Chief Executive Officer"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Dr. McDonough brings global company-building, commercial strategy, and R&amp;D leadership experience to the Company ahead of key clinical milestones<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>NodThera plans to report results from two Phase 2 cardiometabolic trials <\/em><br \/>\n        <em>RESOLVE-1 and RESOLVE-2 in mid-2026 and third quarter 2026 respectively<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>Company preparing to begin cardiometabolic Phase 3 trial in 1H 2027<\/em>\n      <\/p>\n<p align=\"justify\">BOSTON, Feb.  04, 2026  (GLOBE NEWSWIRE) &#8212; NodThera, the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address unmet needs in cardiometabolic and neuroinflammatory diseases driven by the NLRP3\/IL-6\/IL-1 inflammation pathway, announced the appointment of Geoff McDonough, M.D., as Chief Executive Officer. Dr. McDonough is a seasoned physician-executive with extensive global biopharma industry experience who joins NodThera\u2019s management team ahead of a series of significant anticipated clinical milestones.<\/p>\n<p align=\"justify\">\u201cThe NLRP3\/IL-6\/IL-1 pathway underlies several large cardiometabolic and neurologic diseases with significant unmet need,\u201d said Dr. McDonough. \u201cNodThera\u2019s unique brain penetrant and immune-targeted lead molecule, NT-0796, will complete two cardiometabolic Phase 2 trials shortly, and we are preparing to launch a Phase 3 trial in just over a year. These milestones are key to our mission to reach patients and families suffering from diseases driven by chronic inflammation.\u201d<\/p>\n<p align=\"justify\">\u201cGeoff\u2019s insights and expertise will be invaluable as we approach an important series of clinical milestones as NT-0796 moves toward Phase 3 development for cardiometabolic diseases,\u201d said Don Nicholson, Ph.D., Chair of the Board. \u201cGeoff brings an impressive combination of global commercial, strategic and R&amp;D leadership experience that positions him well to lead NodThera into this next phase of growth.\u201d<\/p>\n<p align=\"justify\">Dr. McDonough brings more than two decades of leadership experience. Most recently, he served as President &amp; Chief Executive Officer of Generation Bio (NASDAQ: GBIO). Dr. McDonough previously served as President &amp; CEO of Sobi, overseeing substantial portfolio expansion and international growth. Earlier in his career, Dr. McDonough spent a decade at Genzyme, holding senior roles including President of Genzyme Europe and Senior Vice President &amp; General Manager of the global Lysosomal Storage Diseases business. He trained in internal medicine and pediatrics at Massachusetts General Hospital and Boston Children\u2019s Hospital and earned his M.D. from Harvard Medical School.<\/p>\n<p align=\"justify\">\n        <strong>About RESOLVE-1 and RESOLVE-2 Phase 2 Clinical Trials<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>RESOLVE-1<\/strong> is a cardiometabolic Phase 2 clinical trial designed to evaluate the safety and efficacy of NT-0796 over six months. This trial, the only NLRP3 trial to include patients with type 2 diabetes, evaluates improvements in systemic inflammation (high sensitivity CRP) and cardiometabolic markers, and is fully enrolled with 176 patients randomized to NT-0796 or placebo. This is the largest and longest clinical trial in this class and is on track to read out in mid-2026.<\/p>\n<p align=\"justify\">\n        <strong>RESOLVE-2<\/strong> is a cardiometabolic Phase 2 clinical trial designed to evaluate the safety and efficacy of NT-0796 in combination with a GLP- agonist. This fully-enrolled study will evaluate markers of systemic inflammation and cardiometabolic health and is on track to read out in 3Q 2026.<\/p>\n<p align=\"justify\">\n        <strong>About NLRP3 <\/strong>\n      <\/p>\n<p align=\"justify\">NLRP3 is an upstream activator of proinflammatory cytokines, including IL-6, IL-18 and IL-1\u03b2. Chronic activation of NLRP3 drives pathologic inflammation in cardiometabolic, neurological and other diseases. NLRP3 Inhibition with targeted oral therapies reduces systemic inflammation to a similar degree as biologics and does not cause immunosuppression.<\/p>\n<p align=\"justify\">\n        <strong>About NodThera<\/strong>\n      <\/p>\n<p align=\"justify\">NodThera is the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address unmet needs in cardiometabolic and neuroinflammatory diseases driven by the NLRP3\/IL-6\/IL-1 inflammation pathway.<\/p>\n<p align=\"justify\">NodThera is backed by top-tier investors including Blue Owl Capital, Novo Holdings, F-Prime Capital, 5AM Ventures, Epidarex Capital, Sofinnova Partners and Sanofi Ventures.<\/p>\n<p align=\"justify\">NodThera is headquartered in Boston, Massachusetts, with an R&amp;D base in the UK.<\/p>\n<p align=\"justify\">Learn more at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ram6EDcqSeD4T_fFyjhoFuVxZ-FJpNrWzrGUBBYav4iiOaNscOQIwGaNqdn51MZUSFjskMPmxMsSRa0k16vVuulr4fjMMDDvI-jUgbVcPns=\" rel=\"nofollow\" target=\"_blank\">www.nodthera.com<\/a> or follow the Company on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ss8aqwVXljcWlGB_E9DumB0QF-r2Lo9gO8m9sPe7oDK7ed5H0jZJclxkJzQhNXlcWD9HYT9uLSBMLGiPkxB9yl_2emg4GaWFSvGfm9TNc_pPUMdLfl9xkS1hJn2MePKJ\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.\u00a0<\/p>\n<p>\n        <strong>Investors and Media<\/strong><br \/>\n        <br \/>Argot Partners <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=obJbQry1hTHM1V_PKvmy7afZ9OV2S-8XR7zVKm_n6L5RrQ6xw57UXA4W11bY1UE6gtJMqEhr7W5KDwJNt_tl_EQ-sDV-XtK7VaoELxJabmolcpLLtxSoy1F4NNXzJRlk\" rel=\"nofollow\" target=\"_blank\">nodthera@argotpartners.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODQ4MiM3NDA3NjUxIzIzMDU4MTQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NWJmNDgzODItYjk1NC00OTdmLWFiYzMtYjAyOTBiOWZkNTBjLTEzMTczNjQtMjAyNi0wMi0wNC1lbg==\/tiny\/NodThera.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dr. McDonough brings global company-building, commercial strategy, and R&amp;D leadership experience to the Company ahead of key clinical milestones NodThera plans to report results from two Phase 2 cardiometabolic trials RESOLVE-1 and RESOLVE-2 in mid-2026 and third quarter 2026 respectively Company preparing to begin cardiometabolic Phase 3 trial in 1H 2027 BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) &#8212; NodThera, the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address unmet needs in cardiometabolic and neuroinflammatory diseases driven by the NLRP3\/IL-6\/IL-1 inflammation pathway, announced the appointment of Geoff McDonough, M.D., as Chief Executive Officer. Dr. McDonough is a seasoned physician-executive with extensive global biopharma industry experience who joins NodThera\u2019s management team ahead of a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NodThera Appoints Geoff McDonough, M.D., as Chief Executive Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-933998","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NodThera Appoints Geoff McDonough, M.D., as Chief Executive Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NodThera Appoints Geoff McDonough, M.D., as Chief Executive Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Dr. McDonough brings global company-building, commercial strategy, and R&amp;D leadership experience to the Company ahead of key clinical milestones NodThera plans to report results from two Phase 2 cardiometabolic trials RESOLVE-1 and RESOLVE-2 in mid-2026 and third quarter 2026 respectively Company preparing to begin cardiometabolic Phase 3 trial in 1H 2027 BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) &#8212; NodThera, the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address unmet needs in cardiometabolic and neuroinflammatory diseases driven by the NLRP3\/IL-6\/IL-1 inflammation pathway, announced the appointment of Geoff McDonough, M.D., as Chief Executive Officer. Dr. McDonough is a seasoned physician-executive with extensive global biopharma industry experience who joins NodThera\u2019s management team ahead of a &hellip; Continue reading &quot;NodThera Appoints Geoff McDonough, M.D., as Chief Executive Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-04T15:43:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODQ4MiM3NDA3NjUxIzIzMDU4MTQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NodThera Appoints Geoff McDonough, M.D., as Chief Executive Officer\",\"datePublished\":\"2026-02-04T15:43:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\\\/\"},\"wordCount\":633,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODQ4MiM3NDA3NjUxIzIzMDU4MTQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\\\/\",\"name\":\"NodThera Appoints Geoff McDonough, M.D., as Chief Executive Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODQ4MiM3NDA3NjUxIzIzMDU4MTQ=\",\"datePublished\":\"2026-02-04T15:43:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODQ4MiM3NDA3NjUxIzIzMDU4MTQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODQ4MiM3NDA3NjUxIzIzMDU4MTQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NodThera Appoints Geoff McDonough, M.D., as Chief Executive Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NodThera Appoints Geoff McDonough, M.D., as Chief Executive Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\/","og_locale":"en_US","og_type":"article","og_title":"NodThera Appoints Geoff McDonough, M.D., as Chief Executive Officer - Market Newsdesk","og_description":"Dr. McDonough brings global company-building, commercial strategy, and R&amp;D leadership experience to the Company ahead of key clinical milestones NodThera plans to report results from two Phase 2 cardiometabolic trials RESOLVE-1 and RESOLVE-2 in mid-2026 and third quarter 2026 respectively Company preparing to begin cardiometabolic Phase 3 trial in 1H 2027 BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) &#8212; NodThera, the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address unmet needs in cardiometabolic and neuroinflammatory diseases driven by the NLRP3\/IL-6\/IL-1 inflammation pathway, announced the appointment of Geoff McDonough, M.D., as Chief Executive Officer. Dr. McDonough is a seasoned physician-executive with extensive global biopharma industry experience who joins NodThera\u2019s management team ahead of a &hellip; Continue reading \"NodThera Appoints Geoff McDonough, M.D., as Chief Executive Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-04T15:43:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODQ4MiM3NDA3NjUxIzIzMDU4MTQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NodThera Appoints Geoff McDonough, M.D., as Chief Executive Officer","datePublished":"2026-02-04T15:43:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\/"},"wordCount":633,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODQ4MiM3NDA3NjUxIzIzMDU4MTQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\/","name":"NodThera Appoints Geoff McDonough, M.D., as Chief Executive Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODQ4MiM3NDA3NjUxIzIzMDU4MTQ=","datePublished":"2026-02-04T15:43:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODQ4MiM3NDA3NjUxIzIzMDU4MTQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODQ4MiM3NDA3NjUxIzIzMDU4MTQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nodthera-appoints-geoff-mcdonough-m-d-as-chief-executive-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NodThera Appoints Geoff McDonough, M.D., as Chief Executive Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/933998","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=933998"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/933998\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=933998"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=933998"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=933998"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}